Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
The treatment landscape for diffuse large B‑cell lymphoma includes first‑line regimens like R‑CHOP and Pola‑R‑CHP and advanced options such as CAR‑T cell therapy or bispecific antibodies like Glofitamab.
Explore the latest advancements in diffuse large B‑cell lymphoma with Novotech CRO's comprehensive disease landscape analysis. Gain valuable insights into novel therapeutic strategies, ongoing clinical trials, and future innovations that are transforming the care of diffuse large B‑cell lymphoma.
Diffuse large B‑cell lymphoma accounts for 30‑40% of all non‑Hodgkin lymphoma cases and has a high mortality rate, so the development of targeted and immunotherapies is essential to improve patient outcomes.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers